论文部分内容阅读
选取HSP65-X10-βhCGCTP37融合蛋白作为免疫原,观察其对小鼠黑色素瘤B16-F10的体内抑制作用,以及对荷瘤小鼠生存期的影响,并对其抗肿瘤的作用机理进行初步探讨。以制备的HSP65-X10-βhCGCTP37蛋白免疫C57BL/6J小鼠,2 w免疫1次,共4次。第4次免疫后的第2 w,进行肿瘤攻击实验。HSP65-X10-βhCGCTP37激发的免疫应答对于小鼠黑色素瘤的攻击起到了有效的保护作用,与PBS阴性对照组比较,实验组小鼠的平均肿瘤重量显著降低(P<0.05);并有效延长了荷瘤鼠的生存期;小鼠的黑色素移植瘤的肿瘤病理切片结果显示,疫苗对肿瘤细胞的体内生长有明显的抑制作用,核分裂减少,淋巴细胞浸润增加,有灶性坏死。HSP65-X10-βhCGCTP37蛋白疫苗能有效地抑制小鼠黑色素瘤的生长。
The HSP65-X10-βhCGCTP37 fusion protein was selected as the immunogen to observe its inhibitory effect on mouse melanoma B16-F10 in vivo and its effect on the survival of tumor-bearing mice. The anti-tumor mechanism was also explored. C57BL / 6J mice were immunized with the prepared HSP65-X10-βhCGCTP37 protein and immunized twice a week for 4 times. On the 2nd wk after the 4th immunization, a tumor challenge experiment was performed. The immune response stimulated by HSP65-X10-βhCGCTP37 effectively protected against mouse melanoma. Compared with the PBS-negative control group, the average tumor weight of the mice in the experimental group was significantly decreased (P <0.05) and prolonged effectively Survival of tumor-bearing mice; tumor melanoma xenografts tumor pathology results showed that the vaccine has a significant inhibitory effect on the growth of tumor cells in vivo, reduced mitotic, lymphocytic infiltration, with focal necrosis. HSP65-X10-βhCGCTP37 protein vaccine can effectively inhibit the growth of mouse melanoma.